WO2018170624A1 - Méthode de réduction des expressions de mir-185 et de mir-424 - Google Patents
Méthode de réduction des expressions de mir-185 et de mir-424 Download PDFInfo
- Publication number
- WO2018170624A1 WO2018170624A1 PCT/CN2017/077174 CN2017077174W WO2018170624A1 WO 2018170624 A1 WO2018170624 A1 WO 2018170624A1 CN 2017077174 W CN2017077174 W CN 2017077174W WO 2018170624 A1 WO2018170624 A1 WO 2018170624A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- mir
- expression
- pri
- vector
- microrna
- Prior art date
Links
- 230000014509 gene expression Effects 0.000 title claims abstract description 30
- 108091030938 miR-424 stem-loop Proteins 0.000 title claims abstract description 27
- 108091047758 miR-185 stem-loop Proteins 0.000 title claims abstract description 24
- 238000000034 method Methods 0.000 title claims abstract description 15
- 239000013598 vector Substances 0.000 claims abstract description 17
- 239000013604 expression vector Substances 0.000 claims abstract description 4
- 230000008685 targeting Effects 0.000 claims abstract description 4
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 6
- 239000013612 plasmid Substances 0.000 claims description 6
- 238000003753 real-time PCR Methods 0.000 claims description 5
- 238000000338 in vitro Methods 0.000 claims description 4
- 230000001580 bacterial effect Effects 0.000 claims description 3
- 238000010276 construction Methods 0.000 claims description 3
- 239000012634 fragment Substances 0.000 claims description 3
- 229930027917 kanamycin Natural products 0.000 claims description 3
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 claims description 3
- 229960000318 kanamycin Drugs 0.000 claims description 3
- 229930182823 kanamycin A Natural products 0.000 claims description 3
- 238000012163 sequencing technique Methods 0.000 claims description 3
- 238000000746 purification Methods 0.000 claims description 2
- 230000001105 regulatory effect Effects 0.000 claims description 2
- 238000012772 sequence design Methods 0.000 claims description 2
- 230000009466 transformation Effects 0.000 claims description 2
- 238000011081 inoculation Methods 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 230000002222 downregulating effect Effects 0.000 abstract description 5
- 239000002679 microRNA Substances 0.000 description 14
- 108091070501 miRNA Proteins 0.000 description 13
- 230000030279 gene silencing Effects 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 4
- 230000011987 methylation Effects 0.000 description 4
- 238000007069 methylation reaction Methods 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 108091068954 Homo sapiens miR-185 stem-loop Proteins 0.000 description 2
- 108091032108 Homo sapiens miR-424 stem-loop Proteins 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 238000001823 molecular biology technique Methods 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 108091029523 CpG island Proteins 0.000 description 1
- 108010009540 DNA (Cytosine-5-)-Methyltransferase 1 Proteins 0.000 description 1
- 102100036279 DNA (cytosine-5)-methyltransferase 1 Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 108091027305 Heteroduplex Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 239000012097 Lipofectamine 2000 Substances 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 108091030146 MiRBase Proteins 0.000 description 1
- 108700011259 MicroRNAs Proteins 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- 206010064390 Tumour invasion Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000009400 cancer invasion Effects 0.000 description 1
- 230000004709 cell invasion Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 238000012226 gene silencing method Methods 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
Definitions
- the present invention relates to the field of life sciences, and more particularly to a method of reducing the expression of microRNA-185 and microRNA-424.
- MicroRNA-185 (miR-185) is a 22 nt miRNA located in human chromosome 22ql l.
- DNMT1 methylation-related tumor suppressor miRNA that can be directly targeted.
- the expression of DNMT1 affects the methylation level of the whole genome, which in turn regulates the methylation status of certain genes, affecting gene expression; microRNA
- miR-424 (miR-424) is a miRNA discovered in recent years, which affects the biological effects and development of tumor cells by acting on target genes in various tumors, thereby affecting the biological effects and development of tumor cells.
- miR-424 is a multifunctional miRNA, which is associated with cell invasion and metastasis of cervical cancer, pancreatic cancer, etc.; it is associated with the expression of inflammatory factors such as IL-6 and TNF- ⁇ ; since the miR-424 promoter region has CpG islands It is also associated with methylation-induced gene silencing.
- miRNA silencing is the presentation of artificially synthesized oligonucleotide small molecules into cells, and endogenous miRNAs.
- a heteroduplex allows the miRNA to reduce the inhibition of the target gene to achieve regulation of gene function.
- Silencing of miRNAs is currently difficult to achieve.
- Commonly used methods for silencing miRNA mainly include anti-miR, antagomiR, miRNA sponge, etc. These methods have short effects such as short inter-turn, poor stability, complex construction, high requirements on instrument conditions, and complicated technical operations, which are difficult to achieve, simple, and effective. The effect of miR-185 and miR-424 expression was reduced.
- the object of the present invention is to provide a method for reducing the expression of miR-185 and miR-424, which is simple in design, easy to operate, and can easily and effectively down-regulate the expression of miR-185 and miR-424, Overcoming the deficiencies of the prior art.
- a method for the present invention a method for down-regulating expression of miR-185 and miR-424, and constructing eukaryotic expression targeting miR-185 and miR-424 on a eukaryotic vector pRI-GFP/Neo containing a HI promoter Vector pRI-185-424, which regulates the expression of miR-185 and miR-424 in eukaryotic cells; after transfecting the vector into eukaryotic cells in vitro, the expression of miR-185 and miR-424 was detected by real-time PCR Level.
- the sequences of pRI-GFP/Neo and Tud-185-424 were double-digested with Xho I and Bgl II, and the recovered fragments were purified and ligated overnight at 4 ° C. After ligation, single colonies were picked and inoculated. In LB medium containing l (Vg/ml kanamycin, 12 hours later, the bacterial solution was extracted and sent to Shanghai Yingjun for sequencing. The correctly sequenced vector was the successfully constructed recombinant plasmid pRI-185-424.
- the present invention utilizes a molecular biology technique to construct a eukaryotic expression vector containing Tud-185-424 based on a eukaryotic vector containing a CMV promoter, thereby down-regulating the expression of miR-185 and miR-424; After the vector was transfected into eukaryotic cells in vitro, the expression of miR-185 and miR-424 was detected by a real-time PCR instrument.
- the invention is not only suitable for transfection of cells, but also for the production of whole horizontal transgenic animals.
- FIG. 1 is a schematic diagram showing the structure of the pRI-GFP/Neo vector
- FIG. 2 is a quantitative PCR method for detecting the expression level of miRNA, wherein a. miR-185 expression, b. miR-424 expression.
- Tud RNA targeting hsa-miR-185 and hsa-miR-424 was designed according to the design principle of Tough Decoy RNA (Tud RNA).
- Tud RNA Tough Decoy RNA
- Tud-185-424 The enzyme was digested to obtain the desired Tud-185-424 sequence.
- the nucleotide sequence of Tud-185-424 is shown as SE Q ID No 1.
- 16HBE cells were seeded in a 6-well plate at a density of 30,000/ml, and 10
- Plasmid pRI-185-424 was transfected with Lipofectamine 2000 and continuously cultured at 5% CO 2 at 37 ° C. After 48 sputum, total RNA was extracted from each group, using Realtime.
- miR-185 and miR-424 were detected by PCR, and the results showed that the expression levels of m iR-185 and miR-424 were significantly down-regulated in the pRI-185-424 transfection group (Fig. 2), suggesting that the vector can be used for The expression of miR-185 and miR-424 was reduced.
- the present invention utilizes a molecular biology technique to construct a eukaryotic expression vector containing Tud-185-424 based on a eukaryotic vector containing a CMV promoter, thereby down-regulating the expression of miR-185 and miR-424; After the vector was transfected into eukaryotic cells in vitro, the expression of miR-185 and miR-424 was detected by a real-time PCR instrument.
- the invention is not only suitable for transfection of cells, but also for the production of whole horizontal transgenic animals.
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
L'invention concerne une méthode de réduction des expressions de miR-185 et de miR-424. La méthode comprend la construction d'un vecteur d'expression eucaryote pRI-185-424 ciblant miR-185 et miR-424 sur un vecteur eucaryote pRI-GFP/Neo qui contient un promoteur H1, régulant ainsi négativement les expressions de miR-185 et de miR-424.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2017/077174 WO2018170624A1 (fr) | 2017-03-18 | 2017-03-18 | Méthode de réduction des expressions de mir-185 et de mir-424 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2017/077174 WO2018170624A1 (fr) | 2017-03-18 | 2017-03-18 | Méthode de réduction des expressions de mir-185 et de mir-424 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2018170624A1 true WO2018170624A1 (fr) | 2018-09-27 |
Family
ID=63583994
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/CN2017/077174 WO2018170624A1 (fr) | 2017-03-18 | 2017-03-18 | Méthode de réduction des expressions de mir-185 et de mir-424 |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2018170624A1 (fr) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101368213A (zh) * | 2008-10-13 | 2009-02-18 | 南京大学 | 血清微小核糖核酸试剂盒及其在乙肝早期诊断中的应用 |
| CN101755208A (zh) * | 2007-07-25 | 2010-06-23 | 路易斯维尔大学研究基金会公司 | 作为诊断标记物的外来体相关微rna |
| WO2010138263A2 (fr) * | 2009-05-28 | 2010-12-02 | University Of Massachusetts | Nouveaux virus adéno-associés (aav) et leurs utilisations |
| CN102218144A (zh) * | 2010-04-13 | 2011-10-19 | 江苏命码生物科技有限公司 | 一种调节生物体内微小核糖核酸含量的方法及其用途 |
| CN103920164A (zh) * | 2014-05-05 | 2014-07-16 | 山东大学 | MiR-424-5p在抑制转移性肝癌中的应用 |
-
2017
- 2017-03-18 WO PCT/CN2017/077174 patent/WO2018170624A1/fr active Application Filing
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101755208A (zh) * | 2007-07-25 | 2010-06-23 | 路易斯维尔大学研究基金会公司 | 作为诊断标记物的外来体相关微rna |
| CN101368213A (zh) * | 2008-10-13 | 2009-02-18 | 南京大学 | 血清微小核糖核酸试剂盒及其在乙肝早期诊断中的应用 |
| WO2010138263A2 (fr) * | 2009-05-28 | 2010-12-02 | University Of Massachusetts | Nouveaux virus adéno-associés (aav) et leurs utilisations |
| CN102218144A (zh) * | 2010-04-13 | 2011-10-19 | 江苏命码生物科技有限公司 | 一种调节生物体内微小核糖核酸含量的方法及其用途 |
| CN103920164A (zh) * | 2014-05-05 | 2014-07-16 | 山东大学 | MiR-424-5p在抑制转移性肝癌中的应用 |
Non-Patent Citations (1)
| Title |
|---|
| XING-HUA LIAO ET AL.: "Human Cytomegalovirus Immediate Early Protein 2 Enhances Myocardin-mediated Survival of Rat Aortic Smooth Muscle Cells", VIRUS RESEARCH, vol. 192, 23 August 2014 (2014-08-23), pages 85 - 91, XP029071011, ISSN: 1872-7492 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107502608A (zh) | 用于敲除人ALDH2基因的sgRNA、ALDH2基因缺失细胞株的构建方法及应用 | |
| EP3778892A1 (fr) | Nouveau petit arn activateur | |
| WO2019120132A1 (fr) | Souche génétiquement modifiée pour l'expression hétérologue efficace de disorazole z, agrégat de gènes pour construire la souche et applications correspondantes | |
| CN108467864A (zh) | 一种icam-1基因敲除肿瘤细胞株及其应用 | |
| WO2018170624A1 (fr) | Méthode de réduction des expressions de mir-185 et de mir-424 | |
| WO2018165929A1 (fr) | Vecteur d'expression inhibant le micro-arn double brin, son procédé de mise au point et son application | |
| CN104046635B (zh) | 特异响应逆境信号的nfiS基因的用途及其使用方法 | |
| CN110564743B (zh) | 一种六盘山黄牛circR-UQCC1基因及其过表达载体、构建方法和应用 | |
| CN105462969A (zh) | 猪特异性友好位点Pifs102及其应用 | |
| WO2018170623A1 (fr) | Méthode de réduction des expressions de miarn-152 et de miarn-424 | |
| WO2018170622A1 (fr) | Procédé de régulation négative synchrone des expressions de miarn-152 et de miarn-185 | |
| CN103525854A (zh) | 高基因敲除效率的谢瓦氏曲霉间型变种工程菌株的构建方法 | |
| WO2017214952A1 (fr) | Construction et application d'un vecteur lentiviral pour l'inhibition spécifique de l'expression de l'arnmi-185 humain | |
| WO2018170620A1 (fr) | Vecteur d'expression de deux micro-arn mis sous silence | |
| WO2018170621A1 (fr) | Vecteur d'expression réduisant un micro-r-148a et un micro-r-424 et son application | |
| CN105462986B (zh) | 猪特异性友好位点Pifs302及其应用 | |
| WO2018170619A1 (fr) | Vecteur d'expression inhibant le micro-arn double brin et son application | |
| WO2018170753A1 (fr) | Arn tud pour l'inactivation de miarn-29a, de miarn-152, et de miarn-185, et application de celui-ci | |
| WO2018170751A1 (fr) | Arn tud destiné à antagoniser l'expression d'un micro-arn, et son application | |
| WO2018170757A1 (fr) | Adénovirus ad-29a-185-424-tud recombinant, et construction et application associées | |
| WO2019000151A1 (fr) | Virus adéno-associé recombinant pour inhiber simultanément les expressions de trois micro-arn | |
| CN106591311B (zh) | 核酸及其用途 | |
| WO2018170750A1 (fr) | Arn tud pour supprimer les expressions de miarn-29a, de miarn-148a, et de miarn-152, et application de celui-ci | |
| CN105462970A (zh) | 猪特异性友好位点Pifs501及其应用 | |
| WO2020000467A1 (fr) | Vecteur de surexpression de lncrna db327252 et son procédé de préparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17902192 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 17902192 Country of ref document: EP Kind code of ref document: A1 |